NLS Pharmaceutics Increases Share Capital by CHF 76,439.38
Ticker: NCEL · Form: 6-K · Filed: Apr 15, 2024 · CIK: 1783036
| Field | Detail |
|---|---|
| Company | Nls Pharmaceutics LTD. (NCEL) |
| Form Type | 6-K |
| Filed Date | Apr 15, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: capital-increase, corporate-action, filing-update
TL;DR
NLS Pharma boosted capital by ~CHF 76k via new shares after board OK'd it April 9th.
AI Summary
NLS Pharmaceutics Ltd. filed Amended and Restated Articles of Association on April 15, 2024, reflecting a share capital increase of CHF 76,439.38 through the issuance of new shares. This action follows a board resolution dated April 9, 2024, concerning an increase from the company's capital band (Kapitalband).
Why It Matters
This capital increase could provide NLS Pharmaceutics with additional funds for operations or expansion, potentially impacting its financial health and future growth prospects.
Risk Assessment
Risk Level: low — The filing is a routine update to articles of association following a board resolution, with no immediate negative financial implications disclosed.
Key Numbers
- CHF 76,439.38 — Share Capital Increase (Amount of capital increase through new share issuance.)
Key Players & Entities
- NLS Pharmaceutics Ltd. (company) — Registrant
- April 15, 2024 (date) — Filing date
- April 9, 2024 (date) — Board resolution date
- CHF 76,439.38 (dollar_amount) — Share capital increase amount
FAQ
What is the purpose of the share capital increase?
The filing states the increase is from the Registrant's capital band (Kapitalband) and reflects in the Amended and Restated Articles of Association, but does not explicitly detail the specific use of funds.
When was the board resolution for the capital increase passed?
The board resolution regarding the share capital increase was dated April 9, 2024.
What is the total number of new shares issued?
The filing mentions the increase of share capital by CHF 76,439.38 through the issuance of new shares, but does not specify the exact number of shares.
Where is NLS Pharmaceutics Ltd. headquartered?
NLS Pharmaceutics Ltd. is headquartered in Zurich, Switzerland.
What type of filing is this?
This is a Form 6-K, a Report of Foreign Private Issuer filed with the SEC.
Filing Stats: 358 words · 1 min read · ~1 pages · Grade level 12.2 · Accepted 2024-04-15 16:01:25
Filing Documents
- ea0203562-6k_nlspharma.htm (6-K) — 12KB
- ea020356201ex99-1_nlspharma.htm (EX-99.1) — 228KB
- 0001213900-24-032948.txt ( ) — 241KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. NLS Pharmaceutics Ltd. Date: April 15, 2024 By: /s/ Alexander Zwyer Name: Alexander Zwyer Title: Chief Executive Officer 3